The FDA ruled that makers of generics can continue producing versions of the painkiller Opana ER's older formulation, saying the new version is not a significant improvement when it comes to stopping drug abuse compared with earlier forms that are not abuse-deterrent. The new version is vulnerable to chewing, grinding, cutting and other manipulation, the FDA said. The ruling is expected to raise concerns with some law-enforcement and community groups fighting drug abuse.

Related Summaries